Lee, Jae Cheol, et al. “Real-World Treatment Patterns in Patients With EGFR Mutation-Positive NSCLC Receiving a First-Line, First- or Second-Generation EGFR Tyrosine Kinase Inhibitor in South Korea and Taiwan”. Asian Pacific Journal of Cancer Biology, vol. 6, no. 2, May 2021, pp. 123-32, doi:10.31557/apjcb.2021.6.2.123-132.